Indus Holding AG (INH) News

Form 8-K - Current report

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form ARS - Annual Report to Security Holders

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form DEF 14A - Other definitive proxy statements

Aileron Therapeutics to be Included in the Russell Microcap® Index

Aileron Therapeutics to be Included in the Russell Microcap® Index PR Newswire AUSTIN, Texas, July 1, 2024...

Form 8-K - Current report

Form 3 - Initial statement of beneficial ownership of securities

Form 8-K - Current report

Form 8-K - Current report

Aileron Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights

Announced positive data from Cohort 1 of the Phase 1b clinical trial of LTI-03 in idiopathic pulmonary fibrosis...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aileron Therapeutics to Present at Two Upcoming Investor Conferences

AUSTIN, Texas, May 06, 2024 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. (“Aileron”) (NASDAQ: ALRN), a...

Aileron Therapeutics Announces Closing of Underwritten Registered Direct Offering of up to Approximately $40 Million

AUSTIN, Texas, May 03, 2024 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. (“Aileron”) (NASDAQ: ALRN), a...